Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta-analysis of the liraglutide phase III clinical trial programme

Diabetes, Obesity and Metabolism

Volumn 18, Issue 7, 2016, Pages 707-710

  Montanya, E ^a   Fonseca, V ^b   Colagiuri, S ^c   Blonde, L ^d   Donsmark, M ^e   Nauck, M A ^f  

^a UNIVERSITY OF BARCELONA   (Spain)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d OCHSNER MEDICAL CENTER   (United States)

^e NOVO NORDISK A S   (Denmark)

^f ST JOSEF HOSPITAL   (Germany)

Author keywords

body mass index; glycaemic control; liraglutide; meta analysis; type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; LIRAGLUTIDE; PLACEBO; SITAGLIPTIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

BODY MASS; CORRELATIONAL STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); BLOOD; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; METABOLISM; MIDDLE AGED;

BODY MASS INDEX; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; SITAGLIPTIN PHOSPHATE;

EID: 84959102677     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12617     Document Type: Letter

References (14)

1. Marre M, Shaw J, Brandle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268–278.
2. Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84–90.
3. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473–481.
4. Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care 2009; 32: 1224–1230.
5. Russsell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia 2009; 52: 2046–2055.
6. Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39–47.
7. Pratley RE, Nauck M, Bailey T et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447–1456.
8. Ingwersen SH, Khurana M, Madabushi R et al. Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment. J Clin Pharmacol 2012; 52: 1815–1823.
9. Niswender K, Pi-Sunyer X, Buse J et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab 2013; 15: 42–54.
10. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015; 58: 429–442.
11. Chitnis AS, Ganz ML, Benjamin N, Langer J, Hammer M. Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study. Adv Ther 2014; 31: 986–999.
12. Pratley RE, Nauck MA, Barnett AH et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014; 2: 289–297.
13. Rosenstock J, Shenouda SK, Bergenstal RM et al. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care 2012; 35: 955–958.
14. Seufert J, Bailey TS, Svendsen CB et al. The effect of liraglutide on A1c and body weight is largely dependent on diabetes duration. Diabetes 2013; 62: A266.